J07AH08 - Meningococcus A,C,Y,W-135, Tetravalent Purified Polysaccharides Antigen Conjugated |
Propably not porphyrinogenic |
PNP |
Important Information
In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can lead to a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever.
Side effects
Fever is reported as a very common side effect the meningococcus A, C, Y, W-135 vaccine.
A common adverse reaction of the vaccine that can be confused with an acute porphyric attack is nausea. This side effect may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
The active substances in the meningococcus A,C,Y,W-135 vaccine are conjugates of protein and oligosaccharides and with regards to its pharmacokinetics it has no conceivable porphyrinogenic effects.
Chemical description
The tetravalent meningococcus A, C, W, Y-135 conjugate vaccine consists of oligosaccharides derived from capsular polysaccharides of Neisseria meningitidis serogroups A, C, W and Y, each conjugated to a Corynebacterium diphtheriae-mutant carrier protein (EMA).
Therapeutic characteristics
The Meningococcus A,C,Y,W-135 vaccine is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
It is administered by a single intramuscular injection.
Metabolism and pharmacokinetics
The meningococcus vaccine is not metabolized by the cytochrome P450 system.
References
- Government bodies
- European Public Assessment Report, Menveo (Scientific discussion).European Medicines Agency (EMA). Accessible from: ema.europa.eu #3198
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015) #1860
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Menveo. #3199
Similar drugs
© NAPOS 2024